Pharmacovigilance expert Bart Cobert discusses the FDA and MHRA guidance for non-Corona related clinical trials.
Bart Cobert gives his pharmacovigilance point of view on a recent paper on FDA approval timelines and drug safety issues.
Bart Cobert on the importance of publishing clinical trials data and implications on pharmacovigilance.
This is an interesting article looking at what PV will be in the year 2030.
Bart Cobert highlights the most important changes in the recently revised FDA draft guidance on PMRs.
Bart Cobert explores several important points to take from the still ongoing signal and safety issue with Renitidine recall.
Bart Cobert discusses the major safety issue in the US on e-cigarettes and vaping.
Bart Cobert covers several issues involved in setting up the proposed “Safe Importation Plan” which aims to allow US consumers to get safe and cheaper drugs.
An overview covering a number of things to avoid doing when it comes to drug safety.
